Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...
Investor's Business Daily on MSN2d
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBioAlnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.
Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger ...
Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio.
The U.S. Food and Drug Administration has approved Alnylam Pharmaceuticals drug Amvuttra to treat transthyretin amyloid ...
Canaccord raised the firm’s price target on Alnylam (ALNY) to $390 from $385 and keeps a Buy rating on the shares. The firm noted they ...
Alnylam Pharmaceuticals' shares rose more than 10% on Friday after the drugmaker secured U.S. approval for its heart disease drug, setting the stage for the 23-year-old biotech's next phase of growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback